Article Sidebar

PDF (Tiếng Việt)
Published: 2025-07-28
Abstract Views: 0
Views PDF (Tiếng Việt): 0
DOI: https://doi.org/10.52852/tcncyh.v192i7.3644
Issue
Vol. 192 No. 7 (2025)
Section
Các bài báo
How to Cite
Mai, N. T. T., Phương, V. M., Phương, P. C., Hải, N. T. T., & Phượng, N. T. (2025). 1. Thromboelastometry predicts thrombosis in patients with hepatocellular carcinoma. Journal of Medical Research, 192(7), 1-8. https://doi.org/10.52852/tcncyh.v192i7.3644

1. Thromboelastometry predicts thrombosis in patients with hepatocellular carcinoma

Nguyen Thi Tuyet Mai, Vu Minh Phuong, Pham Cam Phuong, Nguyen Thi Thanh Hai, Nguyen Thuy Phuong

Main Article Content

Abstract

ROTEM is a test to evaluate the overall hemostasis process. To predict the risk of thrombosis, a study was conducted on 125 patients with hepatocellular carcinoma undergoing thromboelastometry from February to December 2024 at Bach Mai Hospital. The results showed that the disease is more common in male/, the most common cause of hepatocellular carcinoma is hepatitis B. The CFT index of INTEM and EXTEM in the group with thrombosis was shorter than the group without thrombosis. The alpha, A10, MCF indexes in INTEM and EXTEM, MCF of FIBTEM in the group with thrombosis were higher than the group without thrombosis with statistical significance at p < 0.05. MCF FIBTEM is the parameter with the best correlation with hypercoagulability in patients with hepatocellular carcinoma, increased MCF of FIBTEM (> 17.5mm) is associated with a 2.488-fold higher risk of portal vein thrombosis.

Article Details

Keywords

Hepatocellular carcinoma, thromboelastometry, ROTEM

References

1. Tripodi A, Salerno F, Chantarangkul V, et al. Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests. Hepatology. 2005; 41(3): 553-558. doi:10.1002/hep.20569.
2. Rautou PE, Caldwell SH, Villa E. Bleeding and Thrombotic Complications in Patients With Cirrhosis: A State-of-the-Art Appraisal. Clin Gastroenterol Hepatol. 2023; 21(8): 2110-2123. doi:10.1016/j.cgh.2023.04.016.
3. European Association for the Study of the Liver. EASL Clinical Practice Guidelines on prevention and management of bleeding and thrombosis in patients with cirrhosis. J Hepatol. 2022; 76(5): 1151-1184. doi:10.1016/j.jhep.2021.09.003.
4. Pan J, Wang L, Gao F, et al. Epidemiology of portal vein thrombosis in liver cirrhosis: A systematic review and meta-analysis. Eur J Intern Med. 2022; 104: 21-32. doi:10.1016/j.ejim.2022.05.032.
5. Fahrendorff M, Oliveri RS, Johansson PI. The use of viscoelastic haemostatic assays in goal-directing treatment with allogeneic blood products – A systematic review and meta-analysis. Scand J Trauma Resusc Emerg Med. 2017; 25: 39. doi:10.1186/s13049-017-0378-9.
6. Janko N, Majeed A, Kemp W, Roberts SK. Viscoelastic Tests as Point-of-Care Tests in the Assessment and Management of Bleeding and Thrombosis in Liver Disease. Semin Thromb Hemost. 2020; 46(6): 704-715. doi:10.1055/s-0040-1715475.
7. Amitrano L, Guardascione MA, Brancaccio V, et al. Risk factors and clinical presentation of portal vein thrombosis in patients with liver cirrhosis. J Hepatol. 2004; 40(5): 736-741. doi:10.1016/j.jhep.2004.01.001.
8. Falanga A, Russo L, Verzeroli C. Mechanisms of thrombosis in cancer. Thromb Res. 2013; 131 Suppl 1: S59-62. doi:10.1016/S0049-3848(13)70024-0.
9. Falanga A, Marchetti M, Vignoli A. Coagulation and cancer: biological and clinical aspects. J Thromb Haemost. 2013; 11(2): 223-233. doi:10.1111/jth.12075.
10. Tripodi A, Primignani M, Chantarangkul V, et al. The coagulopathy of cirrhosis assessed by thromboelastometry and its correlation with conventional coagulation parameters. Thromb Res. 2009; 124(1): 132-136. doi:10.1016/j.thromres.2008.11.008.
11. Caine GJ, Lip GYH, Stonelake PS, Ryan P, Blann AD. Platelet activation, coagulation and angiogenesis in breast and prostate carcinoma. Thromb Haemost. 2004; 92(1): 185-190. doi:10.1160/TH03-11-0679.
12. Thorson CM, Van Haren RM, Ryan ML, et al. Pre-existing hypercoagulability in patients undergoing potentially curative cancer resection. Surgery. 2014; 155(1): 134-144. doi:10.1016/j.surg.2013.06.053.
13. Simpson-Haidaris PJ, Rybarczyk B. Tumors and fibrinogen. The role of fibrinogen as an extracellular matrix protein. Ann N Y Acad Sci. 2001; 936: 406-425.